US 11,590,089 B2 · Beta-2 selective adrenergic receptor agonists

Beta-2 selective adrenergic receptor agonists

AssigneesThe Board of Trustees of the Leland Stanford Junior University, The Regents of the University of California, Friedrich-Alexander-Universität Erlangen-Nürnberg

InventorsRoger Sunahara, Harald Huebner, Jeremy Shonberg, Anne Stößel, Markus Stanek, Dorothée Möller, Mary Joyce Clark, Brian K. Kobilka, Peter Gmeiner, Luis Maul

Life of this patent

Estimating the term…

Abstract

Aspects of the present disclosure include conformationally restricted analogs of catecholamine type compounds (e.g., isoprenaline, adrenaline, noradrenaline) which activate β2AR with high selectivity over β1AR. The subject beta-2 selective adrenergic receptor agonist compounds may serve as bronchiodilators and find use in the treatment of a variety of bronchoconstrictive diseases and conditions. Also provided are compositions and methods for treating preterm labor. A method of treating acute asthma including administration of a subject compound to a subject in need thereof is provided. The subject method can provide for reduced undesirable side effects associated with non-selective β-adrenergic receptor agonism, such as inotropic and chronotropic effects that leads to elevated blood pressure. The compounds can also be used to prevent or treat heart failure. Kits and compositions for practicing the subject methods are also provided.

Claims4

Dependent claims

A method of treating a bronchoconstrictive disease, the method comprising:

administering to a subject in need thereof an effective amount of a β2AR selective compound to ameliorate one or more symptoms associated with undesired and/or uncontrolled bronchoconstriction in the subject, wherein administration is achieved via nebulization or inhalation of the β2AR selective compound, wherein the subject has a heart disease, wherein the β2AR selective compound has the structure:

Dependencies are inferred from the claim text.

Facts

Application

16/768,025Filed 30 Nov 2018 · us provisional application

Priority

4 Dec 2017

Published

US 2020/0360304 A119 Nov 2020

Granted

28 Feb 2023

Term ends

Not estimatedThe source records don’t support an estimate.

Classification5 codes

A61K 31/13
Medicinal preparations containing organic active ingredients: amines
A61K 31/16
Medicinal preparations containing organic active ingredients: amides, e.g. hydroxamic acids
A61K 31/337
Having oxygen as the only ring hetero atom, e.g. fungichromin: having four-membered rings, e.g. taxol
A61K 31/695
Medicinal preparations containing organic active ingredients: silicon compounds